Lung Adenocarcinoma

Oncology
4
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 5 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

HM
Huadong MedicineChina - Hangzhou
1 program
1
Pulmonary segmentectomyPhase 31 trial
Active Trials
NCT07169903Not Yet RecruitingEst. Dec 2033
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QL1706Phase 21 trial
Active Trials
NCT07416058Not Yet RecruitingEst. Dec 2028
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
huCART-meso cellsPhase 11 trial
huCART-meso cellsPhase 1
Active Trials
NCT03054298Completed65Est. Jul 2024
Roche
RocheSTAVANGER NORWAY, Norway
1 program
BevacizumabN/AMonoclonal Antibody1 trial
Active Trials
NCT02093000Completed201Est. Jan 2018
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Tumor MicroenvironmentN/A1 trial
Active Trials
NCT05982574Active Not Recruiting300Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Huadong MedicinePulmonary segmentectomy
Qilu PharmaceuticalQL1706
Gilead ScienceshuCART-meso cells
Heidelberg PharmaTumor Microenvironment
RocheBevacizumab

Clinical Trials (5)

Total enrollment: 566 patients across 5 trials

NCT07169903Huadong MedicinePulmonary segmentectomy

Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT

Start: Oct 2025Est. completion: Dec 2033
Phase 3Not Yet Recruiting
NCT07416058Qilu PharmaceuticalQL1706

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Start: Jan 2026Est. completion: Dec 2028
Phase 2Not Yet Recruiting
NCT03054298Gilead ScienceshuCART-meso cells

CAR T Cells in Mesothelin Expressing Cancers

Start: Apr 2017Est. completion: Jul 202465 patients
Phase 1Completed
NCT05982574Heidelberg PharmaTumor Microenvironment

Tumor Microenvironment

Start: Feb 2016Est. completion: Dec 2026300 patients
N/AActive Not Recruiting
NCT02093000RocheBevacizumab

A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma

Start: Nov 2014Est. completion: Jan 2018201 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)